Genomic Testing: A Powerful Weapon Against Breast Cancer
Abnormal genes can cause breast cells to grow out of control and become cancerous. By identifying specific gene mutations in tumors, doctors can provide improved targeted treatment for these breast cancers.
FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment
The US Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting).
FDA Expands Use of Breast Cancer Rx
For the first time in its history, the US Food and Drug Administration has approved a medication for the pre-surgical (neoadjuvant) treatment of early-stage (I, II) breast cancer.
New Drug for HER2-Positive Breast Cancer
The US Food and Drug Administration has approved a new drug to treat HER2-positive late-stage (metastatic) breast cancer. The drug has been shown to extend remission by about six months.